MorphoSys AG
MORG.DE- Latest Trade
- trading higher18.15EUR
- 0.15
- 0.83%
- As of Jan 29 2023. Values delayed up to 15 minutes
- Day Range
- 17.82 - 18.34
- 52-Week Range
- 11.80 - 29.61
- Previous Close
- 18.00
- Open
- 18.10
- Volume
- 93,647.00
- 3 Month Average Trading Volume
- 7.24
- Shares Out (Mil)
- 34.16
- Market Cap
- 621.31
- Forward P/E
- -1.46
- Dividend Yield
- 0.00
Key Statistics
3.16666667 mean rating - 12 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 2.49
- Price To Book (Quarterly)
- 0.00
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -33.50
- Return On Equity (TTM)
- -30.05
2021 (millions USD)
About MorphoSys AG (MORG.DE)
Company Information
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Address
Semmelweisstr. 7PLANEGG,
82152
Germany
Industry
Biotechnology & Drugs
Executive Leadership
- Marc Cluzel
- Independent Chairman of the Supervisory Board
- Jean-Paul Kress
- Chairman of the Management Board, Chief Executive Officer
- George S. Golumbeski
- Independent Deputy Chairman Member of the Supervisory Board
- Sung H. Lee
- Chief Financial Officer, Member of the Management Board
- Malte Peters
- Chief Research and Development Officer, Member of the Management Board
- Michael Brosnan
- Independent Member of the Supervisory Board
- Sharon Curran
- Independent Member of the Supervisory Board
- Wendy S. Johnson
- Independent Member of the Supervisory Board
- Krisja Vermeylen
- Independent Member of the Supervisory Board
Latest News
- BusinessGerman pharma company MorphoSys's finance head to step down
German pharma company MorphoSys said its finance chief Sung Lee would leave the company for personal reasons in March 2023 and that the company was seeking a successor to Sung, who joined in February 2021.
- MarketsGerman stocks - Factors to watch on January 4
The following are some of the factors that may move German stocks on Tuesday:
- MarketsGerman stocks - Factors to watch on December 13
The following are some of the factors that may move German stocks on Monday
- BusinessVaccine pioneer BioNTech hires former Morphosys exec as finance chief
BioNTech , the Pfizer (PFE.N) partner that invented the Comirnaty COVID-19 vaccine, has appointed former Morphosys (MORG.DE) executive Jens Holstein as chief financial officer to help it grow into a global immunotherapy company.
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,927.60 | 0.12% |
| Copper | 783.30 | 1.20% |
| Brent Crude Oil | 86.66 | -- |
| CBOT Soybeans | 1,512.25 | 0.74% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,070.56 | 0.25% |
| Euro STOXX 50 | 4,178.01 | 0.10% |
| FTSE 100 | 7,765.15 | 0.05% |
| Nikkei 225 | 27,382.56 | 0.07% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes